Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

871 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risk factors for treatment related mortality in childhood acute lymphoblastic leukaemia.
Lund B, Åsberg A, Heyman M, Kanerva J, Harila-Saari A, Hasle H, Söderhäll S, Jónsson ÓG, Lydersen S, Schmiegelow K; Nordic Society of Paediatric Haematology and Oncology. Lund B, et al. Pediatr Blood Cancer. 2011 Apr;56(4):551-9. doi: 10.1002/pbc.22719. Epub 2010 Dec 8. Pediatr Blood Cancer. 2011. PMID: 21298739
Pneumocystis jiroveci pneumonia prophylaxis during maintenance therapy influences methotrexate/6-mercaptopurine dosing but not event-free survival for childhood acute lymphoblastic leukemia.
Levinsen M, Shabaneh D, Bohnstedt C, Harila-Saari A, Jonsson OG, Kanerva J, Lindblom A, Lund B, Andersen EW, Schmiegelow K; Nordic Society of Paediatric Haematology and Oncology (NOPHO). Levinsen M, et al. Among authors: lund b. Eur J Haematol. 2012 Jan;88(1):78-86. doi: 10.1111/j.1600-0609.2011.01695.x. Epub 2011 Oct 2. Eur J Haematol. 2012. PMID: 21854453 Clinical Trial.
DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial.
Nielsen SN, Grell K, Nersting J, Abrahamsson J, Lund B, Kanerva J, Jónsson ÓG, Vaitkeviciene G, Pruunsild K, Hjalgrim LL, Schmiegelow K. Nielsen SN, et al. Among authors: lund b. Lancet Oncol. 2017 Apr;18(4):515-524. doi: 10.1016/S1470-2045(17)30154-7. Epub 2017 Mar 1. Lancet Oncol. 2017. PMID: 28258828 Clinical Trial.
NT5C2 germline variants alter thiopurine metabolism and are associated with acquired NT5C2 relapse mutations in childhood acute lymphoblastic leukaemia.
Tulstrup M, Grosjean M, Nielsen SN, Grell K, Wolthers BO, Wegener PS, Jonsson OG, Lund B, Harila-Saari A, Abrahamsson J, Vaitkeviciene G, Pruunsild K, Toft N, Holm M, Hulegårdh E, Liestøl S, Griskevicius L, Punab M, Wang J, Carroll WL, Zhang Z, Dalgaard MD, Gupta R, Nersting J, Schmiegelow K. Tulstrup M, et al. Among authors: lund b. Leukemia. 2018 Dec;32(12):2527-2535. doi: 10.1038/s41375-018-0245-3. Epub 2018 Sep 10. Leukemia. 2018. PMID: 30201983
Genetic predisposition to PEG-asparaginase hypersensitivity in children treated according to NOPHO ALL2008.
Højfeldt SG, Wolthers BO, Tulstrup M, Abrahamsson J, Gupta R, Harila-Saari A, Heyman M, Henriksen LT, Jónsson ÒG, Lähteenmäki PM, Lund B, Pruunsild K, Vaitkeviciene G, Schmiegelow K, Albertsen BK; Nordic Society of Paediatric Haematology Oncology (NOPHO) group. Højfeldt SG, et al. Among authors: lund b. Br J Haematol. 2019 Feb;184(3):405-417. doi: 10.1111/bjh.15660. Epub 2018 Nov 18. Br J Haematol. 2019. PMID: 30450575 Free article. Clinical Trial.
Low burden of minimal residual disease prior to transplantation in children with very high risk acute lymphoblastic leukaemia: The NOPHO ALL2008 experience.
Ifversen M, Turkiewicz D, Marquart HV, Winiarski J, Buechner J, Mellgren K, Arvidson J, Rascon J, Körgvee LT, Madsen HO, Abrahamsson J, Lund B, Jonsson OG, Heilmann C, Heyman M, Schmiegelow K, Vettenranta K. Ifversen M, et al. Among authors: lund b. Br J Haematol. 2019 Mar;184(6):982-993. doi: 10.1111/bjh.15761. Epub 2019 Jan 24. Br J Haematol. 2019. PMID: 30680711 Free article.
Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia.
Gottschalk Højfeldt S, Grell K, Abrahamsson J, Lund B, Vettenranta K, Jónsson ÓG, Frandsen TL, Wolthers BO, Marquart HV, Vaitkeviciene G, Lepik K, Heyman M, Schmiegelow K, Albertsen BK. Gottschalk Højfeldt S, et al. Among authors: lund b. Blood. 2021 Apr 29;137(17):2373-2382. doi: 10.1182/blood.2020006583. Blood. 2021. PMID: 33150360 Free article. Clinical Trial.
TPMT polymorphisms and minimal residual disease after 6-mercaptopurine post-remission consolidation therapy of childhood acute lymphoblastic leukaemia.
Dreisig K, Brünner ED, Marquart HV, Helt LR, Nersting J, Frandsen TL, Jonsson OG, Taskinen M, Vaitkeviciene G, Lund B, Abrahamsson J, Lepik K, Schmiegelow K. Dreisig K, et al. Among authors: lund b. Pediatr Hematol Oncol. 2021 Apr;38(3):227-238. doi: 10.1080/08880018.2020.1842570. Epub 2020 Nov 18. Pediatr Hematol Oncol. 2021. PMID: 33205673 Clinical Trial.
871 results